Page 108 - Haematologica Vol. 107 - September 2022

ARTICLE - Body Composition Impacts CRS after CART therapy D.M. Cordas dos Santos et al.
external validation. J Immunother Cancer. 2020;8(2):e001403.
42. Rogado J, Sanchez-Torres JM, Romero-Laorden N, et al.
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21-27.
43. Stevenson JKR, Qiao Y, Chan KKW, et al. Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent. Leuk Lymphoma. 2019;60(6):1399-1408.
44. Scheich S, Enssle JC, Mucke VT, et al. Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation. PLoS One. 2019;14(11):e0225035.
45. Wudhikarn K, Bansal R, Khurana A, et al. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer J. 2021;11(7):124.
46. Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;5(1):134.
47. Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499-2513.
48. Emmons R, Niemiro GM, De Lisio M. Hematopoiesis with obesity and exercise: role of the bone marrow niche. Exerc Immunol Rev. 2017;23:82-95.
49. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58(11):727-736.
50. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8(9):673-675.
51. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145(5):2273-2282.
52. Christ A, Latz E. The Western lifestyle has lasting effects on metaflammation. Nat Rev Immunol. 2019;19(5):267-268.
53. Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B- cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4):e002056.
54. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539-1547.
55. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):16-31.
56. Rubin DB, Al Jarrah A, Li K, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536-1542.
Haematologica | 107 September 2022
2107